The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
The transcriptional regulator c-JUN is a key mediator of the metastatic potential and drug resistance in melanoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Additionally, c-JUN induces an EMT-like phenotype switch that may be responsible for the adaptive resistance to BRAF-MEK-ERK pathway inhibition in BRAFV600E melanoma cells [56].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [56]
Citations
Cites
Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources
Huang, D. W., Sherman, B. T., & Lempicki, R. A. (2009) · Nature Protocols · doi:10.1038/nprot.2008.211 · Cited by 35,890 · cited 1×
“Functional category enrichment analysis using the NCBI Database for Annotation, Visualization and IntegratedDiscovery (DAVID) functional annotation toolwas used to identify GO terms (58) for the significant differentially expressed gene set.”
MethodSmyth, G. K. (2004) · Statistical Applications in Genetics and Molecular Biology · doi:10.2202/1544-6115.1027 · Cited by 11,829
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196 · cited 2×
“These morphological and expression pattern alterations were consistent with previous descriptions of EMT programs in epithelial cancers (28) and of the phenotypic switch in melanoma (33).”
BackgroundResultImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Self-citationInhibition of Mutated, Activated BRAF in Metastatic Melanoma
Flaherty, K. T., Puzanov, I., Kim, K. B., Ribas, A., McArthur, G. A., Sosman, J. A., O'Dwyer, P. J., Lee, R. J., Grippo, J. F., Nolop, K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002011 · Cited by 3,103
Self-citationImproved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412690 · Cited by 2,701
Self-citationEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Flaherty, K. T., Robert, C., Hersey, P., Nathan, P., Garbe, C., Milhem, M., Demidov, L. V., Hassel, J. C., Rutkowski, P., Mohr, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203421 · Cited by 2,160
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156
Self-citationCombined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
Larkin, J., Ascierto, P. A., Dréno, B., Atkinson, V., Liszkay, G., Maio, M., Mandalà, M., Demidov, L., Stroyakovskiy, D., Thomas, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408868 · Cited by 2,068
Self-citation
Cited by
Items 101–143 of 143
Shea, A., Lubling, Y., Guerrero-Romero, D., García, R. M., Greenwood, W., O’Reilly, M., Georgopoulou, D., Callari, M., Lerda, G., Wix, S., et al. (2024) · Cancer Research · doi:10.1158/0008-5472.can-24-1703 · Cited by 13
Signaling and transcriptional dynamics underlying early adaptation to oncogenic BRAF inhibition
Flower, C. T., Liu, C., Chuang, H.-Y., Ye, X., Cheng, H., Heath, J. R., Wei, W., & White, F. M. (2024) · Cell Systems · doi:10.1016/j.cels.2025.101239 · Cited by 11
Chromatin assembly factor 1 suppresses epigenetic reprogramming toward adaptive drug resistance
Wang, Z., Wu, R., Nie, Q., Bouchonville, K. J., Diasio, R. B., & Offer, S. M. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2020.12.003 · Cited by 10
“8, 26 We therefore hypothesized that increased chromatin accessibility might facilitate AP1 binding and transcriptional reprogramming to promote vemurafenib resistance.”
BackgroundSeip, K., Jørgensen, K., Haselager, M. V., Albrecht, M., Haugen, M. H., Egeland, E. V., Lucarelli, P., Engebraaten, O., Sauter, T., Mælandsmo, G. M., et al. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.09.023 · Cited by 8
Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer
Rubio-Cuesta, B., Carretero-Puche, C., Llamas, P., Sarmentero, J., Gil-Calderon, B., Lens-Pardo, A., Antón-Pascual, B., Rubio-González, E., Cámara-Jurado, M., Salamanca, J., et al. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03058-6 · Cited by 7
Mulero‐Sánchez, A., Bosma, A. R., Visuvasam, B., Pouliopoulou, N., van de Ven, M., Proost, N., Boeije, M., Lieftink, C., Beijersbergen, R. L., Bernards, R., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03616-z · Cited by 8
“This highlights a previously unap-preciated link between mTOR and JUN in resistance mechanisms and resonates with growing literature demonstrating the role of JUN/AP-1 factors in resistance to targeted therapies [51, 52].”
Kumar, V., Sabaté-Cadenas, X., Soni, I., Stern, E., Vias, C., Ginsberg, D., Mateo, C. R., Pulido, R., Dodel, M., Mardakheh, F. K., et al. (2024) · Oncogene · doi:10.1038/s41388-024-03021-4 · Cited by 7
“Given the established association of EMT with chemoresistance [39, 40] and considering the impact of JUNI on EMT-relevant genes, we aimed to investigate the signi fi cance of JUNI in the survival of cells exposed to UV irradiation or chemotherapeutic drugs.”
Molecular functions of ASK family in diseases caused by stress-induced inflammation and apoptosis
Kojima, K., Ichijo, H., & Naguro, I. (2020) · The Journal of Biochemistry · doi:10.1093/jb/mvaa145 · Cited by 7
Jin, Z., Wu, J., Lin, J., Wang, J., & Shen, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.862803 · Cited by 6
Alvarez-Buylla, E. R., Martínez‐García, J. C., Dávila-Velderrain, J., Domínguez‐Hüttinger, E., & Martínez-Sánchez, M. E. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-89354-9_1 · Cited by 6
Cancer stem cells, plasticity, and drug resistance
Lionetti, M. C., Fumagalli, M. R., & Porta, C. A. M. L. (2020) · Cancer Drug Resistance · doi:10.20517/cdr.2019.112 · Cited by 8
“Early adaptation involving transcriptome reprogramming seems to be particularly relevant even at long time scale, allowing the tumor to survive until a genetic mutation and permanent resistance mechanism is acquired([43,47]).”
BackgroundTaking out the JNK: A window of opportunity to improve cancer therapy
Ferrao, P. T. (2016) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1128515 · Cited by 5
“The ability to target c-JUN through upstream inhibition of its activator enzyme c-JUN-N-terminal kinase (JNK) offers a significant opportunity to target both therapy resistance and phenotype-switching associated with enhanced metastatic potential.(2) The JNK-JUN pathway has been verified as a key pathway in mediating…”
BackgroundMethodSelf-citationHu, J., Ghosh, C., Khaket, T. P., Yang, Z., Tabdili, Y., Alamaw, E. D., Boufraqech, M., Dixon, S. J., & Kebebew, E. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03624-z · Cited by 4
Wang, X., Peng, J., Song, D., Hou, L., Wang, Q., Zhou, Y., Ma, Y., Qiu, C., Guo, Q., & Wang, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1605124 · Cited by 3
JNK-ERK signalling in melanoma: rewired or entangled?
Haass, N. K. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14903 · Cited by 2
Wang, Z., Zou, F., Tian, Y., Xiang, B., Qin, B., & Liu, Y. (2018) · Future Oncology · doi:10.2217/fon-2018-0127 · Cited by 2
CRISPR Screens Identify Essential Cell Growth Mediators in BRAF-inhibitor Resistant MelanomaPreprint
Li, Z., Wang, B., Gu, S., Jiang, P., Sahu, A., Chen, C.-H., Han, T., Shi, S., Wang, X., Traugh, N., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2019.12.16.876631 · Cited by 2
Gautron, A., Bachelot, L., Quéméner, A. M., Corre, S., Aubry, M., Rambow, F., Paris, A., Tardif, N., Leclair, H. M., Coulouarn, C., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.07.08.193102 · Cited by 2
Liu, F., & Lin, J. (2024) · Cancers · doi:10.3390/cancers16132313 · Cited by 2
“The LEF1 transcriptional factor is multi-functional, and its involvement in BRAFi/MEKi resistance has not been well established [38], but it may be related to epithelial–mesenchymal transition.”
BackgroundImpact of circRNA on the complex regulatory network of the cell
Porta, C. A. M. L. (2019) · Non-coding RNA Investigation · doi:10.21037/ncri.2019.05.01 · Cited by 1
Overcoming phenotypic switching: targeting protein-protein interactions in cancer
LADIAS, C. A., Papakotoulas, P., Papaioannou, M., & Papanikolaou, N. A. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00181 · Cited by 1
Mutant RIT1 cooperates with YAP to drive an EMT-like lung cancer state
Rominger, M. C., O’Brien, S., Gupta, S., Moorthi, S., McSharry, M. V., Kamlapurkar, S., Lowe, A. R., Waldum, A., Lo, A., Duke, F. F., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116185 · Cited by 2
“40,41 We therefore tested whether MEK inhibition with the small molecule trametinib 42 could suppress the oncogenic growth of SALE-RY cells, alone or in combination with VT104, 43 an analog of VT3989, a pan-TEAD autopalmitoylation inhibitor that suppresses TEAD-mediated transcription and has shown…”
Zhang, Y., Belote, R. L., Urquijo, M. A., Hansen, M. M. K., Hejna, M., Moustafa, T. E., Liu, T., Lange, D., Vand‐Rajabpour, F., Chang, M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.26.269126 · Cited by 3
Emmons, M. F., Bennett, R. L., Riva, A., Zhang, C., Macaulay, R. J. B., Dupéré-Richer, D., Fang, B., Seto, E., Koomen, J. M., Li, J., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.10.12.511971 · Cited by 1
“These findings are supported by previous work showing that both AP1/Jun and TEAD’s have also are important drivers of BRAFi resistance in melanoma [41, 42].”
ResultFOSL1’s Diverse Roles in Glioma/Glioma Stem Cells and Tu-morigenesis: A Comprehensive ReviewPreprint
Khedri, A., Guo, S., Ramar, V., Hudson, B., & Liu, M. (2023) · Preprints.org · doi:10.20944/preprints202312.1378.v1 · Cited by 1
dos Santos, M. T. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.9.2016.tde-25022016-110122
Combating malignant melanoma with the multifaceted soy-dervied peptide lunasin.
Shidal, C. (2017) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/2713
Targeted Therapies for BRAF-Mutant Metastatic Melanoma
Johnson, D. B., Dummer, R., Flaherty, K. T., & Smalley, K. S. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-46029-1_40-1
Su, Y.-P., Li, G., Ko, M. E., Cheng, H.-J., Zhu, R.-H., Xue, M., Wang, J. K., Lee, J., Frankiw, L. S., Xu, A. M., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/767988
Nuclear NFATc1/Smad3 complexes in Smad4-deficient pancreatic cancer
Hasselluhn, M. C. (2019) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7778
Targeted Therapies for BRAF-Mutant Metastatic Melanoma
Johnson, D. B., Dummer, R., Flaherty, K. T., & Smalley, K. S. M. (2020) · Springer eBooks · doi:10.1007/978-3-030-05070-2_40
Heinzerling, L., Hartmann, A., & Hund, M. (2019) · Springer eBooks · doi:10.1007/978-3-662-58012-7_1
Cancer cells survival is dependent on the lincRNA JUNIPreprint
Kumar, V., Sabaté-Cadenas, X., Soni, I., Stern, E., Vias, C., Ginsberg, D., Dodel, M., Mardakheh, F. K., Shkumatava, A., & Shaulian, E. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.06.21.496924
“As c-Jun can modulate melanoma cells plasticity (24) we examined the expression of a set of known c-Jun”
BackgroundShea, A., Eyal-Lubling, Y., Guerrero-Romero, D., García, R. M., Greenwood, W., O’Reilly, M., Georgopoulou, D., Callari, M., Lerda, G., Wix, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.01.10.523259
“The mechanism 505 of response to olaparib described here is akin to previous reports of phenotypic switching in response to 506 treatment (52-55).”
ResultData from Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies
Wajapeyee, N., & Gupta, R. (2023) · doi:10.1158/0008-5472.c.6513472.v1
Data from Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma
Thakur, R., Laye, J. P., Lauss, M., Diaz, J. M. S., O'Shea, S. J., Poźniak, J., Filia, A., Harland, M., Gascoyne, J., Randerson‐Moor, J. A., et al. (2023) · doi:10.1158/1078-0432.c.6527877
Kumar, V., Sabaté-Cadenas, X., Soni, I., Stern, E., Vias, C., Ginsberg, D., Mateo, C. R., Pulido, R., Dodel, M., Mardakheh, F. K., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.23.563579
Ammar, U. M., El‐Din, M. M. G., Abdel‐Maksoud, M. S., Ali, E., El–Gamal, M. I., Mahmoud, Z., Ahn, S., Nguyen, N. H. A., Kim, E., Park, J., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.145699 · Cited by 1
Pre-existing cell states predict resistance to multiple treatments
Schaff, D. L., White, P. E., Cote, C. J., Watterson, G., Lin, K. Z., Fasse, A. J., Zhang, N. R., & Shaffer, S. M. (2026) · Cell Genomics · doi:10.1016/j.xgen.2026.101191 · Cited by 2
“These clusters also showed higher expression of previously identified markers of resistance to BRAFi and MEKi, including EGFR , NGFR , AXL , NT5E , and JUN 16,19,26,45,53–56 (Figure 4C).”
Identification et modulation des voies moléculaires impliquées dans l’agressivité du mélanome cutané
Gautron, A. (2019) · theses.fr (ABES) · doi:10.70675/b9c75939z7407z49abzafcbze6e92703d459
Rôle de c-Jun dans la réponse aux inhibiteurs de la voie des MAPK dans les mélanomes
Pohorecka, M. (2018) · theses.fr (ABES) · doi:10.70675/4cf7db7bz9142z4de8zbcbbzd5860991d571
Ahmad, Z. E., Ludwig, K., Matthies, A. O., Bosserhoff, A., & Kappelmann‐Fenzl, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146459
“For c-Jun, it has been shown that enhanced signaling causes activation via phosphorylation and that increased c-Jun abundance correlates with metastatic potential and BRAF inhibitor resistance [49,50].”
Closing the adaptive window: immune–metabolic strategies to constrain melanoma therapy resistance
Riccardo, F., Conti, L., Defilippi, P., Arina, P., Audrito, V., & Calautti, E. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1954638
Metadata
- Authors
- Ramsdale, R., Jorissen, R. N., Li, F. Z., Al-Obaidi, S., Ward, T., Sheppard, K. E., Bukczynska, P. E., Young, R. J., Boyle, S. E., Shackleton, M., Bollag, G., Long, G. V., Tulchinsky, E., Rizos, H., Pearson, R. B., McArthur, G. A., Dhillon, A. S., & Ferrao, P. T.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- The University of Melbourne (AU)
- Plexxikon (United States) (US)
- The University of Sydney (AU)
- University of Leicester (GB)
- Melanoma Institute Australia (AU)
- Corresponding author
- Ramsdale, Rachel
- Jorissen, Robert N.
- Ferrao, Petranel T.
- ORCID
- Venue
- Science Signaling
- Published
- 2015-08-18
- Volume
- 8
- Issue
- 390
- Pages
- ra82-ra82
- ISSN
- 1937-9145 (ISSN-L)
- 1945-0877
- OpenAlex
- W2318400076
- Cited by
- 143
- References
- 63
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 8 · 2023: 10 · 2022: 11 · 2021: 14 · 2020: 18 · 2019: 22 · 2018: 15 · 2017: 18 · 2016: 14
- FWCI
- 6.80
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Locations
- Science Signaling (publishedVersion)
- PubMed (publishedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Peter MacCallum Cancer Foundation
- CASS Foundation
- National Health and Medical Research Council of Australia (1042980)
- China Scholarships Council
- Cancer Therapeutics CRC
- Australian National Health and Medical Research Council
- Pfizer Australia
- Victorian Endowment for Science, Knowledge and Innovation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- c-Jun, BRAF inhibitor resistance, BRAF V600-mutant melanoma, epithelial-mesenchymal transition, mesenchymal phenotype, Sprouty4, LEF1, JNK, transcriptional cofactors, drug resistance, BRAF/MEK inhibitors, cell migration, cell death
- MeSH terms
- Animals, Humans, Melanoma, Membrane Proteins, Microscopy, Fluorescence, Nerve Tissue Proteins, Phenotype, Blotting, Western, Gene Expression Regulation, Neoplastic, Mice, SCID, Mice, Inbred NOD, Mice, Knockout, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Gene Expression Profiling, MAP Kinase Signaling System, Xenograft Model Antitumor Assays, RNA Interference, Cell Line, Tumor, Tumor Burden, Protein Kinase Inhibitors, Intracellular Signaling Peptides and Proteins, JNK Mitogen-Activated Protein Kinases, Proto-Oncogene Proteins B-raf, Interleukin Receptor Common gamma Subunit, Epithelial-Mesenchymal Transition
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.